PharmiWeb.com - Global Pharma News & Resources
24-Mar-2022

Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022

Immutep announces publication of TACTI-002 abstract at ESMO’s European Lung Cancer Congress 2022

 

  • New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in second line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients
  • Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activity in this difficult to treat patient population with limited treatment options
  • Overall Response Rate (ORR) of 6 percent (2/36) and Disease Control Rate (DCR) of 36 percent (13/36) in the intent to treat population; both partial responses are confirmed and durable
  • Important additional data on safety and efficacy including 6 months Overall Survival (OS), Tumour Growth Kinetics, and details of the confirmed partial responses will be presented in the poster at ELCC

 

Sydney, Australia, March 24, 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that new interim data from 2nd line NSCLC patients (Part B) of its phase II TACTI-002 trial has been published in an abstract today in advance of ESMO’s European Lung Cancer Congress (ELCC) 2022. ELCC 2022 will now be taking place in a virtual only format from 30 March 2022 to 2 April 2022.

 

Title: Results of phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

Abstract: Available at https://tinyurl.com/ycx5hwhr

 

The related poster presentation with new and updated data that are not part of the abstract will now be released by ELCC on 29 March 2022 at 12:00 noon, CEST and will subsequently be made available on Immutep’s website at www.immutep.com.

Editor Details

Last Updated: 24-Mar-2022